Bioequivalence and Bioavailability Forum

drugs of long half life [Design Issues]

posted by jag009  – NJ, 2013-04-02 18:01 (4831 d 07:08 ago) – Posting: # 10329
Views: 9,551

Hi Helmut,

❝ ❝ 90% CI computation will be done using the intersubject CV

❝

❝ Nope. The residual variance in a parallel design is also the total. What Niazi writes:

The width of the confidence interval is determined by the within-subject variance (between-subject variance for parallel group studies) and the number of subjects in the study.

is wrong (or another example of sloppy terminology). In a parallel design between-subject variance is not accessible – only total (or pooled if you prefer).

Agreed There is only one value for us to use anyway.
Question, the anova model (GLM) will only contain 1 factor, correct?

Thanks
John

Complete thread:

• drugs of long half life Ken Peh 2013-03-31 06:43 
  • drugs of long half life jag009 2013-04-02 15:17
    • drugs of long half life Helmut 2013-04-02 15:34
      • drugs of long half lifejag009 2013-04-02 16:01
        • drugs of long half life Helmut 2013-04-02 16:40
          • parallel FDA d_labes 2013-04-04 08:33
            • parallel FDA jag009 2013-04-05 18:01
            • parallel FDA jag009 2013-04-05 21:10
              • random repeated parallel FDA d_labes 2013-04-08 08:29
                • Proc Mixed: random repeated parallel FDA jag009 2013-04-08 15:36
                  • Proc Mixed: parallel groups with different variabilities d_labes 2013-04-08 16:41
                    • Proc Mixed: parallel groups with different variabilities jag009 2013-04-08 20:22
    • drugs of long half life Ken Peh 2013-04-04 15:03
      • drugs of long half life jag009 2013-04-05 17:45